FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today highlighted the company’s clinical development priorities for 2009 as part of its fourth quarter and year end 2008 financial results conference call. Significant updates included notification that the U.S. Food and Drug Administration (FDA) has agreed with the development programs of elvitegravir, GS 9350 and a fixed-dose regimen combining elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate), discussion of timelines for darusentan clinical announcements in 2009 and an increased emphasis on efforts to progress the development of compounds to treat hepatitis C virus (HCV) infection and liver disease.
